Morphic Holding Inc (OQ:MORF)

Latest 10 SEC filings (by transaction date) for MORF within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET October 22nd, 2019
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Aug 2/19 Aug 1/19 Goyal Vikas Direct Ownership Stock Option (right to buy Common Stock) A - Grant, award or other under Rule 16b-3(d) 24,000  
Jul 1/19 Jul 1/19 Slattery Joseph P Direct Ownership Common Stock P - Open market or private purchase 6,667 $15.00
Jul 1/19 Jul 1/19 Stampacchia Otello Indirect Ownership Series B Preferred Stock C - Conversion -1,978,779  
Jul 1/19 Jul 1/19 Stampacchia Otello Indirect Ownership Series A Preferred Stock C - Conversion -857,470  
Jul 1/19 Jul 1/19 Stampacchia Otello Indirect Ownership Common Stock P - Open market or private purchase 133,333 $15.00
Jul 1/19 Jul 1/19 Stampacchia Otello Indirect Ownership Common Stock C - Conversion 1,978,779  
Jul 1/19 Jul 1/19 Stampacchia Otello Indirect Ownership Common Stock C - Conversion 857,470  
Jul 1/19 Jul 1/19 Omega Fund V, L.P. Direct Ownership Series B Preferred Stock C - Conversion -1,978,779  
Jul 1/19 Jul 1/19 Omega Fund V, L.P. Direct Ownership Series A Preferred Stock C - Conversion -857,470  
Jul 1/19 Jul 1/19 Omega Fund V, L.P. Direct Ownership Common Stock P - Open market or private purchase 133,333 $15.00
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for MORF within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET October 22nd, 2019
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Aug 2/19 Aug 1/19 Goyal Vikas Direct Ownership Stock Option (right to buy Common Stock) A - Grant, award or other under Rule 16b-3(d) 24,000  
Jul 2/19 Jul 1/19 Glaxosmithkline Plc Indirect Ownership Series B preferred stock C - Conversion -830,489  
Jul 2/19 Jul 1/19 Glaxosmithkline Plc Indirect Ownership Series A preferred stock C - Conversion -1,469,950  
Jul 2/19 Jul 1/19 Glaxosmithkline Plc Indirect Ownership Common Stock P - Open market or private purchase 333,333 $15.00
Jul 2/19 Jul 1/19 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 830,489  
Jul 2/19 Jul 1/19 Glaxosmithkline Plc Indirect Ownership Common Stock C - Conversion 1,469,950  
Jul 1/19 Jun 28/19 Novo Holdings A/S Direct Ownership SERIES B CONVERTIBLE PREFERRED STOCK C - Conversion -1,978,779  
Jul 1/19 Jun 28/19 Novo Holdings A/S Direct Ownership COMMON STOCK P - Open market or private purchase 666,667 $15.00
Jul 1/19 Jun 28/19 Novo Holdings A/S Direct Ownership COMMON STOCK C - Conversion 1,978,779  
Jul 1/19 Jul 1/19 Slattery Joseph P Direct Ownership Common Stock P - Open market or private purchase 6,667 $15.00
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now
Comment On!
140

Twitter

Search (past week) for $MORF

StockTwits